Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report

This work was supported by NIH grants R01CA183559-02 (to H.T. Kim). J.R. Brown acknowledges support from National Comprehensive Cancer Network, from NCI (R01CA213442 and P01CA206978), and from the Susan and Gary Rosenbach Fund for Lymphoma Research and the Melton Family Fund for CLL Research. The CIBMTR is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24CA076518 from the NCI, the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement (4U10HL069294) from NHLBI and NCI; a contract (HHSH250201200016C) with Health Resources and Services Administration (HRSA/DHHS); two grants (N00014-17-1-2388 and N0014-17-1-2850 from the Office of Naval Research; and grants from Actinium Pharmaceuticals, Inc., Amgen, Inc., Amneal Biosciences, Angiocrine Bioscience, Inc., anonymous donation to the Medical College of Wisconsin, Astellas Pharma US, Atara Biotherapeutics, Inc., Be the Match Foundation, Bluebird bio, Inc., Bristol-Myers Squibb Oncology, Celgene Corporation, Cerus Corporation, Chimerix, Inc., Fred Hutchinson Cancer Research Center, Gamida Cell Ltd., Gilead Sciences, Inc., HistoGenetics, Inc., Immucor, Incyte Corporation, Janssen Scientific Affairs, LLC, Jazz Pharmaceuticals, Inc., Juno Therapeutics, Karyopharm Therapeutics, Inc, Kite Pharma, Inc., Medac, GmbH, MedImmune, The Medical College of Wisconsin, Mediware, Merck & Co, Inc., Mesoblast, MesoScale Diagnostics, Inc., Millennium, the Takeda Oncology Co., Miltenyi Biotec, Inc., National Marrow Donor Program, Neovii Biotech NA, Inc., Novartis Pharmaceuticals Corporation, Otsuka Pharmaceutical Co, Ltd., PCORI, Pfizer, Inc, Pharmacyclics, LLC; PIRCHE AG, Sanofi Genzyme, Seattle Genetics, Shire, Spectrum Pharmaceuticals, Inc., St. Baldrick's Foundation, Sunesis Pharmaceuticals, Inc., Swedish Orphan Biovitrum, Inc., Takeda Oncology, Telomere Diagnostics, Inc., and University of Minnesota.